Pulmonx Corporation

LUNG Healthcare Medical Devices

Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024. In the quarter to June 2026, revenue fell 4.62%, EPS grew 36.8%, free cash flow fell 31.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

1.78 0.07 −3.78%
Market cap
$79.5M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
3/9
Altman Z
−4.84
Beneish M
−3.38
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

2 3 3 3
ROE
(73.73%) (77.19%) (86.22%) (88.87%)
ROA
(37.13%) (36.97%) (39.31%) (36.74%)
ROIC
(175.58%) (158.98%) (153.90%) (141.03%)
Return on Tangible Assets
(62.50%) (64.41%) (70.10%) (69.12%)
Average Days of Receivables
54.94 48.69 44.64 51.12
Free Cash Flow per Share
(0.80) (0.81) (0.70) (0.72)
Free Cash Flow
(32.57) (32.83) (29.41) (30.67)
Other line items

Show all line items

Columns are period end dates